CAR-T cell treatment was published in the CAR-T cell special edition of the Vaccinnes journal

The Üsküdar TRGENMER team, which has been working with the target of a patient potential cleared from cancer for many years by increasing the memory cell potential as well as recognizing and killing cancer with the Car-T cell treatment they developed against cancer, is getting closer to their goal step by step. Now, in vitro laboratory studies of CAR-T cell treatment have been published in the CAR-T cell special edition of the SCI-indexed journal Vaccines. 'ALLBiMEM' trademark registration was made for 0 Üsküdar products that produce CAR-T cells locally in Türkiye.

In vitro laboratory studies of transgenic CAR-T cell treatment being developed against Acute Lymphoblastic Leukemia (ALL) cancer was published in a special edition, which has been supported between July 2021 and July 2023 since the opening of TRGENMER center in the field of Cancer Immunotherapy supported by the Health Institutes of Türkiye (TÜSEB).

 “The hope is raising for the patients to be completely cured of cancer”

Üsküdar University Faculty of Engineering and Natural Sciences, Department of Molecular Biology and Genetics Instructor Cihan Taştan informed Car-T cell treatment.

Taştan said that they aim to create a cancer-free patient potential for many years by increasing the potential of memory cells and added, “The Car-T cell treatment we developed against cancer is personalized and has the ability to recognize and kill cancer cells. It has the potential to kill all cancer cells in the patient at once due to its more specific, targeted killing compared to conventional cancer treatments. This rises hope that the patient will be completely cured of cancer. With this project, we can normally produce soldier cells and we know that we can kill cancer clearly. While giving these cells to the patient, we paid attention to the fact that they were both soldiers and memory cells. Thus, we aim to increase the memory cell potential so that the patient does not receive any treatment in the following years after eliminating the cancer completely from the patient in the first stages, and we aim to create a patient potential who has been got rid of cancer for many years.”.

“We are trying to raise researchers like raising a seed”

Taştan highlighted that all the studies carried out within the scope of the article were carried out by the researchers at Üsküdar University TRGENMER center and said, “All the studies we have carried out within the scope of our article are carried out by our researchers at Üsküdar University TRGENMER center. Gamze Gülden, Berranur Sert, Yasin Ay and Nulifer Neslihan Tiryaki are our postgraduate researchers in our Molecular Biology department. Tarık Teymur is our senior undergraduate student in the Department of Molecular Biology and Genetics. In our TRGENMER center, we strive to raise our country's need for expert researchers like raising a seed from scratch by finding and raising our quality and successful students during their undergraduate years.”.

 “We will have entered a period where medicine called CAR-T cells can be used”

Stating that that the preparations for clinical trials that are the third phase, are planned as of July 2023, Asst. Prof. Cihan Taştan said, “Currently, our transgenic mouse studies, in which we have established the ALL cancer model, is continuing until July. We are planning the preparations of our clinical trial studies, which is the third phase, as of July 2023. Our researchers in our project will also support clinical production by completing GCP and GMP certification trainings in this context. By entering the clinical stages, we will enter a period in which Türkiye can use smart living medicine in certain types of cancer, that is, medicine that we call CAR-T cells.”.

Prof. Nevzat Tarhan is among the authors of the article…

Expressing that President of Üsküdar University Prof. Nevzat Tarhan is also an author in the article, Taştan said, “Our President of the university Prof. Nevzat Tarhan, who inspired many prestigious studies in the world standard and produce products, is also an author in our article. Moreover, I would also like to thank our professors Dr. Abhinava K. Mishra from the University of California Santa Barbara and Acıbadem Labcell Laboratory Director Prof. Ercüment Ovalı.”.

Please click here to read the full article:

 Üsküdar News Agency (ÜNA)